Clinical pharmacodynamics of quinolones

被引：68

作者：

Ambrose, PG

Bhavnani, SM

Owens, RC

机构：

[1] Cognigen Corp, Div Infect Dis, Buffalo, NY 14221 USA

[2] Univ Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY USA

[3] Maine Med Ctr, Portland, ME 04102 USA

[4] Univ Vermont, Coll Med, Burlington, VT USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2003年 / 17卷 / 03期

关键词：

D O I：

10.1016/S0891-5520(03)00061-8

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Pharmacokinetics-pharmacodynamics (PK-PD) describes the relationship between drug concentrations and the agent's pharmacologic or toxicologic effects. This article focuses on fundamental PK-PD concepts as they apply to quinolone antimicrobial agents. The application of this knowledge is of tremendous value to the clinician, drug developer, and regulator because PK-PD principles form the very basis of modern antimicrobial chemotherapeutics.

引用

收藏

页码：529 / +

页数：17

相关论文

共 37 条

[1] Pharmacokinetics-pharmacodynamics of cefepime and piperacillin-tazobactam against Escherichia coli and Klebsiella pneumoniae strains producing extended-spectrum β-lactamases:: Report from the ARREST program [J].

Ambrose, PG ;

Bhavnani, SM ;

Jones, RN .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (05) :1643-1646

[2] Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].

Ambrose, PG ;

Grasela, DM ;

Grasela, TH ;

Passarell, J ;

Mayer, HB ;

Pierce, PF .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797

[3]

AMBROSE PG, 2002, 42 INT C ANT AG CHEM

[4] Pharmacodynamics of fluoroquinolones in experimental models of endocarditis [J].

Andes, DR ;

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 27 (01) :47-50

[5] COMPARATIVE-STUDY WITH ENOXACIN AND NETILMICIN IN A PHARMACODYNAMIC MODEL TO DETERMINE IMPORTANCE OF RATIO OF ANTIBIOTIC PEAK CONCENTRATION TO MIC FOR BACTERICIDAL ACTIVITY AND EMERGENCE OF RESISTANCE [J].

BLASER, J ;

STONE, BB ;

GRONER, MC ;

ZINNER, SH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (07) :1054-1060

[6] EARLY TERMINATION OF A PROSPECTIVE, RANDOMIZED TRIAL COMPARING TEICOPLANIN AND FLUCLOXACILLIN FOR TREATING SEVERE STAPHYLOCOCCAL INFECTIONS [J].

CALAIN, P ;

KRAUSE, KH ;

VAUDAUX, P ;

AUCKENTHALER, R ;

LEW, D ;

WALDVOGEL, F ;

HIRSCHEL, B .

JOURNAL OF INFECTIOUS DISEASES, 1987, 155 (02) :187-191

[7]

CHAMBERS HF, 1984, REV INFECT DIS, V6, pS870

[8]

Craig W A, 1989, Infect Dis Clin North Am, V3, P407

[9] Does the dose matter? [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 2001, 33 :S233-S237

[10] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].

Craig, WA .

CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10

← 1 2 3 4 →